IndietroFemale Reproductive Physiology and Disorders: Oogenesis, Ovarian & Uterine Cycles, Hormonal Regulation, and Sexually Transmitted Infections
Guida di studio - Note intelligenti
Appunti personalizzati basati sui tuoi materiali, ampliati con definizioni chiave, esempi e contesto.
Female Reproductive Physiology
Oogenesis
Oogenesis is the process of producing female gametes (ova) and begins during the fetal period. It involves a series of mitotic and meiotic divisions that result in mature ova.
Oogonia: Diploid stem cells that divide by mitosis to produce primary oocytes.
Primary oocytes: Enter meiosis I but are arrested in late prophase I until puberty.
Secondary oocytes: Produced after completion of meiosis I; arrested in metaphase II and only complete meiosis II if fertilization occurs.
Ova: Mature female gametes produced after completion of meiosis II.
Key differences from spermatogenesis:
Production of primary oocytes occurs only during fetal development.
Meiosis in primary oocytes is arrested in late prophase I and resumes years later.
Meiosis II in secondary oocytes is arrested in metaphase II and only completed upon fertilization.
Relationship Between Oocytes and Follicles
Ovarian follicles are the functional units of the ovary, each enclosing a single oocyte surrounded by supporting cells. Follicles progress through several developmental stages:
Primordial follicle: Single layer of squamous cells around the primary oocyte.
Primary follicle: Single layer of cuboidal cells (granulosa) around the primary oocyte.
Secondary follicle: Multiple layers of granulosa cells surround the primary oocyte.
Vesicular (antral) follicle: Tertiary follicle with a fluid-filled cavity (antrum).
Just before ovulation, the primary oocyte inside a vesicular follicle resumes meiosis and becomes a secondary oocyte.
Follicle Fate: Atresia and Ovulation
Atresia: Programmed cell death (apoptosis) of oocyte and surrounding cells; 99.9% of follicles are never recruited.
Ovulation: Each month after puberty, a select few primary oocytes are activated inside vesicular follicles. One dominant follicle is selected to ovulate.
Products of Meiosis in Females
After meiosis I, two haploid cells of different sizes are produced:
First polar body: Small cell, almost devoid of cytoplasm.
Secondary oocyte: Large cell with most of the cytoplasm and organelles.
The secondary oocyte arrests in metaphase II and is released during ovulation. If fertilized, it completes meiosis II, yielding:
Ovum: Large cell with enough cytoplasm to nourish the fertilized egg.
Second polar body: Small cell lacking cytoplasm, degenerates and dies.
Ovulation
Ovulation is the process by which the ovary wall ruptures, expelling the secondary oocyte into the peritoneal cavity. This typically occurs mid-cycle and is triggered by hormonal changes.
Mittelschmerz: A twinge of pain felt by some women at ovulation.
1–2% of ovulations may release more than one oocyte, potentially resulting in fraternal twins.
Comparison of Oogenesis and Spermatogenesis
Oogenesis and spermatogenesis differ in the number of functional gametes produced, timing, and error rates.
Oogenesis produces one viable haploid ovum and two to three haploid polar bodies.
Spermatogenesis produces four viable sperm.
Oogenesis begins in fetal life and ends at menopause; spermatogenesis begins at puberty and continues into old age.
Error rate: Oogenesis (~20%) is higher than spermatogenesis (3–4%).
Male (Spermatogenesis) | Female (Oogenesis) | |
|---|---|---|
Total Time to Produce One Gamete | 74 days | 13–50 years |
Occurrence During Lifetime | Puberty to old age | Begins in fetal life, ends at menopause |
Number of Gametes per Meiotic Division | 4 equal-size sperm | 1 large ovum and 2–3 small polar bodies |
Number of Gametes per Lifetime | >1 trillion | |
Error Rate | 5% | 20% |
Cells Surrounding Developing Gametes | Sertoli (sustentocyte) cells | Many granulosa cells |
The Ovarian Cycle
Phases of the Ovarian Cycle
The ovarian cycle is a monthly (~28 day) series of events associated with maturation of the oocyte. It consists of two consecutive phases:
Follicular Phase (days 1–14): Growth of vesicular follicles; variable in length.
Luteal Phase (days 15–28): Corpus luteum activity; more consistent in duration.
Ovulation occurs midcycle, separating the two phases.
Development and Fate of Ovarian Follicles
Follicles develop from primordial to primary, secondary, and vesicular stages. After ovulation, the ruptured follicle forms the corpus luteum.
Follicular Phase
Several follicles become sensitive to FSH and begin to grow.
One dominant follicle outcompetes others and continues to develop.
Primary oocyte of dominant follicle completes meiosis I to form secondary oocyte and first polar body just before ovulation.
Oocyte stops meiosis at metaphase II.
Luteal Phase
After ovulation, the ruptured follicle collapses and granulosa cells enlarge to form the corpus luteum.
Corpus luteum secretes progesterone and some estrogen.
If no pregnancy occurs, corpus luteum degenerates into corpus albicans (scar) in ~10 days, and the endometrium begins to erode.
If pregnancy occurs, corpus luteum produces hormones that sustain pregnancy until the placenta takes over.
Regulation of Female Reproductive System
Hormonal Regulation of the Ovarian Cycle
The ovarian cycle is regulated by a complex interplay of hormones from the hypothalamus, pituitary, and ovaries.
Before puberty, ovaries secrete small amounts of estrogen, inhibiting hypothalamic release of GnRH.
At puberty, if leptin levels are adequate, hypothalamus becomes less estrogen-sensitive, releasing GnRH, which stimulates FSH and LH release from the pituitary.
FSH and LH stimulate follicle growth, maturation, and estrogen secretion.
Increasing estrogen levels exert negative feedback, inhibiting GnRH, FSH, and LH release, except for the dominant follicle.
Positive feedback from high estrogen levels triggers an LH surge, leading to ovulation and formation of the corpus luteum.
Corpus luteum secretes progesterone and estrogen; rising levels inhibit FSH and LH (negative feedback).
If no fertilization occurs, corpus luteum degenerates, hormone levels fall, and the cycle restarts.
The Uterine (Menstrual) Cycle
Phases of the Uterine Cycle
The uterine cycle consists of cyclic changes in the functional endometrium in response to fluctuating ovarian hormone levels, coordinated with the ovarian cycle.
Menstrual Phase (days 1–5): Ovarian hormones are at lowest levels; functional layer of endometrium detaches and is shed (menstrual flow lasts 3–5 days).
Proliferative (Preovulatory) Phase (days 6–14): Rising estrogen levels prompt regeneration of the new stratum functionalis layer; cervical mucus thins to facilitate sperm passage; ends at ovulation.
Secretory (Postovulatory) Phase (days 15–28): Endometrium prepares for embryo implantation; rising progesterone from corpus luteum prompts secretion of nutrients and thickening of cervical mucus; if no fertilization, corpus luteum degenerates and cycle restarts.
Correlation of Hormones and Structural Changes
Anterior pituitary hormones (FSH, LH) and ovarian hormones (estrogen, progesterone) regulate structural changes in the ovary and uterus throughout the cycle.
FSH and LH peaks correspond to follicular development and ovulation.
Estrogen and progesterone levels regulate endometrial growth and shedding.
Clinical Considerations
Homeostatic Imbalance: Amenorrhea
Strenuous physical activity can delay menarche and disrupt the menstrual cycle, causing amenorrhea (cessation of menstruation).
Low body fat in female athletes reduces leptin, which is needed for normal reproductive cycles.
Increasing body fat can restore normal cycles.
Effects of Estrogens and Progesterone
Estrogens promote oogenesis, follicle growth, and exert anabolic effects on the reproductive tract.
Induce secondary sex characteristics: breast growth, increased subcutaneous fat (hips, breasts), widening of pelvis.
Metabolic effects: maintain low total blood cholesterol, high HDL, facilitate calcium uptake.
Progesterone works with estrogen to regulate the uterine cycle, promote changes in cervical mucus, and prepare breasts for lactation.
Placental progesterone during pregnancy inhibits uterine motility.
Leptin plays a role in signaling the brain that puberty may occur.
Menopause
Peak reproductive capability in females is around the late 20s.
Menopause: cessation of ovulation and menstruation for 1 year; ovaries stop producing estrogens.
Results in atrophy of reproductive organs and breasts, hot flashes, thinning of skin, loss of bone mass, increased cardiovascular risk, depression, and irritability.
Female Sexual Response
Mechanisms and Characteristics
Initiated by touch and psychological stimuli.
Clitoris is homologous to the male penis; vestibular gland is homologous to the male bulbo-urethral gland.
Orgasm is not necessary for reproduction; females have no refractory period.
Female libido is prompted by dehydroepiandrosterone (DHEA), an androgen from the adrenal cortex.
Sexually Transmitted Infections (STIs)
Overview
STIs (also called STDs or VDs) are the most important cause of reproductive disorders.
The U.S. has the highest rates of infection among developed countries.
Latex condoms help prevent spread.
Bacterial and Parasitic STIs
Chlamydia
Most common bacterial STI in the U.S.; caused by Chlamydia trachomatis.
Responsible for 25–50% of all diagnosed cases of pelvic inflammatory disease.
Symptoms: urethritis, penile/vaginal discharges, abdominal/rectal/testicular pain, painful intercourse, irregular menses.
Only 20% of women and 10% of men have symptoms; left untreated, can lead to sterility.
Newborns can contract conjunctivitis and respiratory tract infections from infected birth canal.
Treatment: antibiotics.
Gonorrhea
Bacterial infection of mucosa of reproductive and urinary tracts; caused by Neisseria gonorrhoeae.
Most infections are asymptomatic.
In males: urethritis, painful urination, discharge of pus from penis.
In females: abdominal discomfort, vaginal discharge, abnormal uterine bleeding, possible urethral symptoms.
Untreated can cause urethral constriction, inflammation, pelvic inflammatory disease, and sterility.
Treatment: antibiotics; resistant strains are becoming prevalent, requiring at least two antibiotics.